Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 822,858 shares, a growth of 62.2% from the November 30th total of 507,439 shares. Approximately 15.5% of the shares of the company are short sold. Based on an average daily volume of 181,013 shares, the short-interest ratio is currently 4.5 days. Based on an average daily volume of 181,013 shares, the short-interest ratio is currently 4.5 days. Approximately 15.5% of the shares of the company are short sold.

Analyst Ratings Changes

MNPR has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Wednesday, October 8th. Leerink Partnrs raised Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Chardan Capital raised their target price on Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Sunday, November 9th. Finally, Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $106.20.

Monopar Therapeutics Trading Down 4.7%

NASDAQ MNPR traded down $3.20 during trading hours on Monday, reaching $65.57. 483,823 shares of the company’s stock were exchanged, compared to its average volume of 214,428. The firm has a fifty day moving average of $79.24 and a 200-day moving average of $60.49. Monopar Therapeutics has a one year low of $21.00 and a one year high of $105.00. The stock has a market cap of $438.01 million, a PE ratio of -19.06 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In related news, CFO Quan Anh Vu bought 1,500 shares of Monopar Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was acquired at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the completion of the purchase, the chief financial officer owned 1,500 shares in the company, valued at approximately $104,925. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MNPR. AlphaQuest LLC grew its holdings in Monopar Therapeutics by 8.5% during the 3rd quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock worth $158,000 after acquiring an additional 151 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics in the 3rd quarter worth $28,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics in the second quarter valued at about $34,000. Finally, JPMorgan Chase & Co. increased its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.